Glenview Trust Co Acquires 3,130 Shares of Astrazeneca Plc $AZN

Glenview Trust Co lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 65.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,923 shares of the company’s stock after acquiring an additional 3,130 shares during the period. Glenview Trust Co’s holdings in Astrazeneca were worth $1,390,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Triumph Capital Management bought a new stake in Astrazeneca in the 3rd quarter worth about $25,000. Bangor Savings Bank grew its position in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new stake in Astrazeneca in the 4th quarter worth about $30,000. Rakuten Investment Management Inc. bought a new stake in Astrazeneca in the 3rd quarter worth about $31,000. Finally, YANKCOM Partnership bought a new stake in Astrazeneca in the 4th quarter worth about $31,000. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Up 0.1%

AZN opened at $187.24 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $290.39 billion, a price-to-earnings ratio of 28.11, a PEG ratio of 1.54 and a beta of 0.26. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The company’s 50-day moving average price is $191.60 and its two-hundred day moving average price is $183.22.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts expect that Astrazeneca Plc will post 9.62 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Citigroup assumed coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They issued a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Thursday, May 14th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.